Joseph Schwartz
Stock Analyst at Leerink Partners
(4.10)
# 518
Out of 5,124 analysts
164
Total ratings
34.31%
Success rate
20.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $22.54 | +210.56% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.28 | +1.54% | 13 | Dec 29, 2025 | |
| APLT Applied Therapeutics | Downgrades: Market Perform | $2 → $1 | $0.11 | +843.40% | 3 | Dec 3, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $80.57 | +98.59% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $8.82 | +58.73% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $1.17 | +70.94% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $60.07 | -0.12% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $15.44 | +3.63% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $22.31 | +168.94% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $61.07 | +88.32% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $65 → $72 | $72.25 | -0.35% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $45.95 | +91.51% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $22.35 | -32.89% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $15.75 | +26.98% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $175.07 | -34.31% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $9.99 | +20.12% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $38.37 | -27.03% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $35.80 | +11.73% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.07 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $5.49 | +118.58% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.38 | +2,010.82% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $1.19 | -15.97% | 4 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $76.70 | -37.42% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $24.05 | -25.16% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $81.49 | -58.28% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $209.29 | -22.12% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $10 | $2.56 | +290.63% | 7 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $6.84 | +382.46% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.27 | +406.33% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $22.94 | +30.78% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $82.27 | -63.53% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $2.08 | +476.92% | 2 | Sep 26, 2017 |
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $22.54
Upside: +210.56%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.28
Upside: +1.54%
Applied Therapeutics
Dec 3, 2025
Downgrades: Market Perform
Price Target: $2 → $1
Current: $0.11
Upside: +843.40%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $80.57
Upside: +98.59%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $8.82
Upside: +58.73%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $1.17
Upside: +70.94%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $60.07
Upside: -0.12%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $15.44
Upside: +3.63%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $22.31
Upside: +168.94%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $61.07
Upside: +88.32%
Oct 27, 2025
Downgrades: Market Perform
Price Target: $65 → $72
Current: $72.25
Upside: -0.35%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $45.95
Upside: +91.51%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $22.35
Upside: -32.89%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $15.75
Upside: +26.98%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $175.07
Upside: -34.31%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $9.99
Upside: +20.12%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $38.37
Upside: -27.03%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $35.80
Upside: +11.73%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.07
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $5.49
Upside: +118.58%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.38
Upside: +2,010.82%
Feb 9, 2024
Downgrades: Market Perform
Price Target: $1
Current: $1.19
Upside: -15.97%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $76.70
Upside: -37.42%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $24.05
Upside: -25.16%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $81.49
Upside: -58.28%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $209.29
Upside: -22.12%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $10
Current: $2.56
Upside: +290.63%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $6.84
Upside: +382.46%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.27
Upside: +406.33%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $22.94
Upside: +30.78%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $82.27
Upside: -63.53%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $2.08
Upside: +476.92%